CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy

(RTTNews) - CERo Therapeutics Holdings, Inc. (CERO) fell 12.77 percent to $6.05 on Friday, down $0.88, after announcing that the U.S. Food and Drug Administration granted Fast Track Designation to its lead investigational compound, CER-1236, for Acute Myeloid Leukemia. The stock opened at $6.40 and traded between $5.41 and $6.70, compared to a previous close of $6.93 on the New York Stock Exchange. Trading volume surged to 4.3 million shares, well above the average of 1.1 million. Shares now sit at the bottom of their 52-week range of $5.41 to $896.00, highlighting ongoing volatility despite the regulatory milestone.